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ABSTRACT
Estrogen regulation of the male skeleton was first clearly demonstrated in patients with aromatase deficiency or a mutation in the ERa
gene. Estrogen action on the skeleton is thought to occur mainly through the action of the nuclear receptors ERa and ERb. Recently, in
vitro studies have shown that the G protein–coupled receptor GPR30 is a functional estrogen receptor (ER). GPR30-deficient mouse
models have been generated to study the in vivo function of this protein; however, its in vivo role in the male skeleton remains
underexplored. We have characterized size, body composition, and bone mass in adult male Gpr30 knockout (KO) mice and their wild-
type (WT) littermates. Gpr30 KO mice weighed more and had greater nasal-anal length (p<.001). Both lean mass and percent body fat
were increased in the KO mice. Femur length was greater in Gpr30 KO mice, as was whole-body, spine, and femoral areal bone mineral
density (p<.01). Gpr30 KO mice showed increased trabecular bone volume (p<.01) and cortical thickness (p<.001). Mineralized
surfacewasincreasedinGpr30KO mice(p<.05).Bromodeoxyuridine (BrdU) labelingshowedgreaterproliferationinthegrowth plateof
Gpr30 KO mice (p<.05). Under osteogenic culture conditions, Gpr30 KO femoral bone marrow cells produced fewer alkaline
phosphatase–positive colonies in early differentiating osteoblast cultures but showed increased mineralized nodule deposition in
mature osteoblast cultures. Serum insulin-like growth factor 1 (IGF-1) levels were not different. These data suggest that in male mice,
GPR30 action contributes to regulation of bone mass, size, and microarchitecture by a mechanism that does not require changes in
circulating IGF-1.  2011 American Society for Bone and Mineral Research.
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Introduction
B
one is a dynamic compartmentalized organ composed of
mineralized, stromal, and hematopoietic marrow compart-
ments. Estrogen (E) signaling plays a critical role in many
mechanisms required for proper bone growth and metabolism.
Estrogens are synthesized from androgen precursors by the
aromatase enzyme and historically have been thought to act
mainlythroughtheactionsofestrogenreceptora(ERa)andERb.
The importance of the action of estrogens on the human male
skeleton has been demonstrated convincingly in patients with
aromatase (estrogen synthase) deficiency
(1–7) and loss of
signaling through the ERa receptor.
(8) Male patients deficient
in either the aromatase enzyme or ERa have exhibited low bone
mass and delayed growth plate closure. Mouse models of
aromatase or ERa deficiency have shown that estrogens are also
important in the regulation of bone mass and metabolism in
male mice.
(9–11)
Our understanding of the complexity of estrogen action has
been expanded by the recent identification of the orphan G
protein–coupled receptor GPR30 as an ER. In 2005, two groups
showed that 17b-estradiolbinds toand signals through it, leading
to the designation of GPR30 as GPER1 in International Union of
Pharmacology nomenclature.
(12,13) GPR30 is a Gs-coupled seven-
pass transmembrane protein originally cloned by multiple groups
in the late 1990s.
(14–18) In vitro it has been found to be activated
by estrogen and G1, a GPR30-specific agonist,
(19) and to induce
cAMP elevation, intracellular calcium mobilization, and transacti-
vation of epidermal growth factor receptors (EGFRs).
(20–24) These
signaling events may originate from GPR30 localized to the
plasma membrane
(21,22,24) or within an intracellular membrane
compartment.
(23,25) Initial human tissue expression analysis of
ORIGINAL ARTICLE J JBMR
Received in original form March 2, 2010; revised form June 22, 2010; accepted August 2, 2010. Published online August 23, 2010.
Address correspondence to: Orhan K O ¨z, MD PhD, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9058, USA.
E-mail: Orhan.Oz@utsouthwestern.edu
Journal of Bone and Mineral Research, Vol. 26, No. 2, February 2011, pp 298–307
DOI: 10.1002/jbmr.209
 2011 American Society for Bone and Mineral Research
298GPR30 showed expression in skeletal muscle, heart, lung, liver,
kidney, and brain,
(14) with subsequent studies showing a similar
distribution that included adipose in mice. Subsequently,
expression has been shown inconnectivetissues suchascartilage
and bone.
(26,27) Expression in the human growth plate cartilage
declinesaspuberty progresses.
(26)In bone,GPR30hasbeen found
to be expressed in osteoblasts, osteocytes, and osteoclasts.
(27) In
immortalized rat calvarial preosteoblasts, Runx2, a critical
regulator of osteoblast cell differentiation, was shown to
upregulate Gpr30 gene expression. This resulted in increased
cellular proliferation in these osteoblast progenitors.
(28) Com-
bined,theresultsofthisstudyandtheexpressionanalysisstrongly
suggest a role for GPR30 in skeletal metabolism.
The in vivo function of GPR30 has been explored only recently
ingeneticallydefinedmousemodels.FoursuchmodelsofGPR30
deficiency have been created using either homologous recombi-
nation to insertionally disrupt the coding exon
(29,30) or Cre-lox
technology to remove it.
(31,32) Skeletal biology has been studied
in a limited fashion. Martensson and colleagues reported a small
age-dependent decrease in crown-rump and femur lengths,
measures of skeletal growth, in Gpr30 KO female mice but not
males. In follow-on studies using these mice, Windahl and
colleagues were able to show that estradiol treatment of
ovariectomized mice reduced longitudinal skeletal growth, as
measured by femur length, and decreased growth plate height
in WT not Gpr30 KO mice.
(33) Male mice were not studied in this
gonadectomized estradiol treatment paradigm. From these
reports, it is clear that the in vivo role of GPR30 in the male
skeleton remains underexplored. Therefore, we undertook
studies to better understand the in vivo role of GPR30 in the
male skeleton. We determined the effect of Gpr30 knockout on
growth plate proliferative activity, bone mass, and structure in
male Gpr30 null mice. Further, we studied in vitro differentiation
ofosteoblastandosteoclastprecursors.Allstudieswereperform-
ed using a previously developed mouse model in which the
Gpr30 gene locus is completely disrupted.
(29)
Materials and Methods
Animals
The University of Texas Southwestern Medical Center Institu-
tional Animal Care and Use Commitee (IACUC) approved all
protocols. The animals were maintained in a controlled
environment of 12hours of light/12hours of dark cycles at an
ambient temperature of 228C. Standard irradiated rodent chow
and water were provided ad libitum. Mice carrying a Gpr30 null
mutation were created by targeted disruption of the gene with a
Neo cassette and have been described previously.
(29) In our
laboratories, the mutation is maintained on a hybrid C57Bl6/J
and 129SvEvTac background. Breeding nonsibling animals
heterozygous for the null mutation generated 4-month-old
homozygous null males and WT littermates.
Morphometric measurements
Body weight and nasal-anal (NAL) length measurements were
determined at the time of sacrifice. Mice were anesthetized via
intraperitonealinjectionoftribromoethanol(Avertin)(1.25%w/v,
0.2mL/10g of body weight) prior to measurement. NAL was
measured using digital calipers (Mitutoyo Corporation, Kawasaki,
Japan). Femur length and midshaft diameters were determined
at the time of animal euthanization. Femoral midshaft diameters
were measured at the inferior edge of the linea aspera.
Dual-energy X-ray absorptiometry (DXA)
Whole-body densitometry (n¼18 WT, n¼22 Gpr30 KO) was
performed using the PIXIMUS densitometer (GE Lunar Corporation,
Madison, WI, USA) equipped with software Version 2.10. By
convention,theheadwasexcludedfromallregionsofinterestused
in whole-body analyses. Total tissue mass was computed using a
region of interest that excluded the head. Body fat (g) was
calculatedfromthesoftwarecomputedpercentbodyfatmultiplied
by the total tissue mass. Lean tissue mass (g) was calculated by
subtractingbonemineralcontent(g)andfatmass(g)fromthetotal
tissue mass. Whole-body, lumbar spine, and femur areal bone
mineral density (aBMD) measures were determined from the
whole-body scans using the appropriate regions of interest.
Growth plate labeling
BrdU labeling was used as an in vivo assay of growth plate
proliferativeactivity(n¼8WT,n¼9Gpr30KO).BrdU(100mLofa
70mg/mL solution) was loaded into a 1003D Alzet osmotic pump
(Cupertino, CA, USA) according to the manufacturer’s instruc-
tions. Three days prior to euthanization of the mice, the pump
was implanted intraperitoneally. An effective dose of 7mg of
BrdU per animal was administered.
(34) Femurs for BrdU
immunostaining were processed, embedded in paraffin, and
sectioned in the University of Texas Southwestern Medical
Center Molecular Pathology Core facility. Tissue sections were
probed subsequently with an anti-BrdU Immunohistochemistry
Kit (Oncogene, San Diego, CA, USA) according to the
manufacturer’s instructions. BrdU
þ chondrocytes were deter-
mined microscopically at 200  magnification and scored as
positive cells per 100 cells counted.
Static and dynamic histomorphometry
To label the skeleton, tetracycline HCL (Sigma, St Louis, MO, USA)
in aqueous solution (0.03mg/g) was given i.p. at 10 and 4 days
prior to euthanization. The left tibia was harvested for
histomorphometry and stored in 70% ethanol until analysis
(n¼9 WT, n¼8 Gpr30 KO). After dehydration in a graded series
of alcohol, the bones were processed undecalcified in methyl
methacrylate as described previously.
(35) Then 10-mm-thick
sections were obtained in the longitudinal plane using a
Reichert Polycut E microtome (Leica Microsystems, Bannock, IL,
USA). Histomorphometric examination was performed via
computer monitor on images captured from an Aus Jena
microscope equipped with a video camera (Optronics, Goleta,
CA, USA) and histomorphometry software (Bioquant Nova II,
Nashville, TN, USA). Static measurements of osteoid indices and
cellular parameters were performed on toluidine blue–stained
sections. Measurements on trabecular bone were taken at a
distance of at least 1mm from the growth plate to prevent
inclusion of primary spongiosa. Fluorochrome-based indices of
bone formation were measured in unstained sections. Speci-
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to define the measured parameters is that recommended by the
Histomorphometry Nomenclature Committee of the American
Society for Bone and Mineral Research.
(36) Abbreviations in
the text are OS/BS (osteoid surface/bone surface), Ob.S/BS
(osteoblast surface/bone surface), MS/BS (total mineralizing
surfaces (singleþdouble)/bone surface), BFR (bone-formation
rate surface referent), Oc.S/BS (osteoclast surface/bone surface),
and ES/BS (eroded surface/bone surface). BFR was calculated
using ½ single labeled surfaces plus all double-labeled surfaces.
Micro–computed tomographic (mCT) imaging
mCT imaging of the right femur (n¼9 per genotype) was
performed using a Siemens Inveon CT/PET Multimodality system
(Siemens Medical Solutions, Inc., Knoxville, TN, USA). Imaging
was performed at 80kV and 500mA with a focal spot of 58mm.
Under high magnification, the effective pixel size was 11.34mm.
Reconstructed images were analyzed on an Inveon Research
Workplace (Siemens Medical Solutions) using manufacturer-
supplied software. Trabecular bone regions of interest (ROIs)
were drawn approximately 180mm from the growth plate and
extended proximally 200 pixels along the cortical wall. The
trabecular bone was segmented from the bone marrow and
analyzed to determine the trabecular bone volume fraction (BV/
TV), trabecular bone surface area per unit volume (BSA/BV),
trabecular thickness (Tb.Th.), trabecular number (Tb.N.), and
trabecular spacing (Tb.Sp.). Trabecular pattern factor (TPF), a
measure of the connectedness of the trabecular structure within
an ROI, also was calculated. The smaller the TPF index, the more
connected is the trabecular bone.
(37) Midshaft cortical wall
thickness (Ct.Th.) was measured on a coronal projection image.
Fourmeasurementsweretakenperpendiculartothecorticalwall
on either side of the shaft and averaged.
Serum IGF-1 levels
Blood was obtained by closed cardiac puncture at the time of
euthanization.Serum was harvested from blood by centrifugation
following clot formation and stored at  808C to prevent protein
degradation prior to analysis. Total IGF-1 serum levels (n¼15 per
genotype) were measured after acid-ethanol extraction using an
IGF-1 RIA (DSL-2900, Diagnostic Systems Laboratories, Webster,
TX, USA) according to manufacturer’s instructions.
Cell culture
In vitro osteoblastogenesis
The proximal and distal ends of femurs were removed aseptically.
Marrow cells were harvested by centrifugation through the bone
at10,000g. Harvested marrowcellswere cultured in12-well plates
containing osteogenic medium [15% fetal bovine serum (Atlanta
Biologicals,Norcross,GA,USA)ina-MEM(Invitrogen,Carlsbad,CA,
USA) plus 5mM b-glycerol phosphate (Sigma) plus 1mM
ascorbate 2-phosphate (Wako Chemicals, Richmond, VA, USA)].
For colony-forming units fibroblast (CFU-F) assays, cells were
seeded ata density of0.6 10
6 cellsper welland 1 10
6 cells per
wellforcolony-forming unitsosteoblast(CFU-Ob)assays.One-half
the medium was replaced with fresh medium every 3 days. The
cultures(CFU-F)wereterminatedat7daysandstainedforalkaline
phosphatase expression (Sigma Kit 86R-1KT). Mineralized nodule
formation (CFU-Ob) was allowed to proceed by culturing the cells
to confluence (usually total of 14 to 20 days). Nodules then were
stainedwith40mMalizarinred(S),pH10.8,anddissolvedindH2O
(MP Biomedicals, Solon, OH, USA). Quantification of CFU-F and
CFU-Ob cultures was conducted by counting macroscopic
colonies and alizarin red (S)
þ nodules, respectively. The assays
were repeated three times.
In vitro osteoclastogenesis
Bone marrow cells were plated in osteoclastogenic medium
[10% FBS (Atlanta Biologicals) in a-MEM (Invitrogen) plus
5ng/mL of macrophage colony-stimulating factor (M-CSF; R&D
Systems, Minneapolis, MN, USA) plus 50ng/mL of sRANKL (R&D
Systems)]. The cells were seeded in a 24-well plate at a density of
2.5 10
5 cells per well. One-half the medium was replaced with
fresh mediumevery 3days. Cultures wereterminatedonday7of
culture and stained for tartate-resistant acid phosphatase
(TRACP) according to the manufacturer’s directions (Sigma Kit
387A-1KT). Osteoclasts were identified as multinucleated
TRACP
þ cells. The assays were scored by averaging the number
of osteoclasts per low-power field in at least three fields per well.
The assay was repeated three times.
Statistical analysis
Data are expressed as mean SEM. Student’s t test was used to
determine statistical significance. In all instances, p<.05 was
taken to be statistically significant.
Results
Gpr30 inactivation causes increased body size and
growth plate proliferation without changes in
circulating IGF-1
Gpr30 KO mice had an increased body weight (30.98 versus
24.85g, p<.0001; Fig. 1A,B) at 4 months of age. The NAL of the
Gpr30 KO mice was significantly higher than in WT males (98.07
versus 93.19mm, p<.001; Fig. 1C). Appendicular skeletal growth
wasassessedbyfemoralmeasurements.FemorallengthinGpr30
KO mice was increased when compared with WT mice (15.95
versus 15.59mm, p<.01; Fig. 2A). Femoral midshaft diameter
(MSD), a measure of femoral radial growth, showed an increase
of 7% in dorsal-ventral growth in Gpr30 KO mice was observed
when compared with WT littermates (1.34 versus 1.24mm,
p<.001; Fig. 2B). However, there was no statistical difference in
mediolateral growth (1.83 versus 1.80mm; Fig. 2C). Interestingly,
serum IGF-1 levels were not different between the two
genotypes (253 15.31 versus 247.67 31.08ng/mL).
We hypothesized that the increased long bone growth seen
in male Gpr30 KO mice might be caused by increased growth
plate proliferation. To test this hypothesis, immunohistochem-
istry was performed on distal femoral growth plates following
in vivo labeling with BrdU. Gpr30 KO mice had an increased
number of BrdU
þ chondrocytes per column (Fig. 3, p<.05).
Staining differences were particularly apparent in the hyper-
trophic chondrocytes.
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appendicular bone mass by DXA
DXA was used to determine bone mineral density (BMD) of WT
and Gpr30 KO mice at 4 months of age. At this age, whole-
body aBMD was elevated in Gpr30 KO mice (53.88 versus
47.93mg/cm
2, p<.01; Table 1). In addition, these mice showed
increased spinal (62.51 versus 54.19mg/cm
2, p<.001; Table 1)
and femoral BMD (78.08 versus 68.38mg/cm
2, p<.001; Table 1).
Lean body mass (23.41 versus 19.9g) and percentage body fat
(13% to 17.1%) were increased significantly in the Gpr30 KO mice
(Table 1).
Fig. 1. Gpr30 KO mice have increased nasal-anal length and body weight at 4 months of age. (A) Representative image of 4-month-old WT and Gpr30 KO
mice. (B) Body weight of WT and Gpr30 KO mice. (C) Nasal-anal lengths (NALs) of WT and Gpr30 KO mice.
 p<.0001 versus WT.
Fig. 2. Gpr30 KO mice have increased femoral size. (A) Femur length of WT and Gpr30 KO mice. (B) Midshaft dorsal ventral femoral diameter (MSD) of WT
and Gpr30 KO mice. (C) Midshaft mediolateral femoral diameter of WT and gpr30 KO mice.
 p<.01 versus WT.
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connected trabecular bone and thicker femoral cortical
bone by mCT analysis
mCT scanning of the distal femur was used to evaluate the effect
of GPR30 deficiency on trabecular bone. Male Gpr30 KO mice
showed increased trabecular bone volume, connectivity, and
trabecular thickness and decreased trabecular spacing in the
distal femur (Table 1 and Fig. 4). BV/TV (%) was increased in the
Gpr30 KO mice (58.5% versus 43.0%, p<.01; Table 1). Trabecular
thickness (70.72 versus 55.05mm, p<.06; Table 1) was increased
in the Gpr30 KO mice, with an associated decrease in trabecular
spacing (49.88 versus 74.19mm
 1, p<.001; Table 1). The more
connected trabecular bone network of the Gpr30 KO mice was
reflected in the negative TPF, whereas the WT mice had a
positive TPF (–4.7 versus 3.8, p<.001; Table 1).
GPR30 deficiency causes increased mineralized surface,
as measured by histomorphometry
Static and dynamic histomorphometric analysis of the proximal
tibia was used to determine the effect of Gpr30 inactivation on
cellular surfaces and mineralization in cancellous bone. Dynamic
Fig. 3. Gpr30 KO mice have higher proliferative activity within the
growth plate by anti-BrdU immunostaining. (A) Representative image
of anti-BrdU staining within the WT femoral growth plate. (B) Represen-
tative image of anti-BrdU staining within the Gpr30 KO femoral
growth plate. (C) Microscopic count of BrdU
þ chondrocytes.
 p<.05
versus WT.
Table 1. Bone Mass and Body Composition, MicroCT Analysis,
and Histomorphometry
WT Gpr30KO
DEXA analysis
BMD (mg/cm
2)
Whole body 47.93 0.74 53.88 0.69
a
Spine 54.19 1.19 62.51 1.31
a
Femur 68.38 1.68 78.08 1.47
a
Body composition
%Body fat 13.0 0.45 17.1 1.25
b
Lean mass (g) 19.9 0.39 23.41 0.34
a
MicroCT of trabecular bone and cortical thickness
f
BV/TV (%) 43 2.1 58.5 3.1
b
BSA/BV (mm
 1)4 0  3.9 29.16 1.8
b
Tb.Th. (mm) 55.1 1.6 70.7 4.3
b
Tb.N. (mm
 1) 7.8 0.2 8.3 0.1
c
Tb.Sp. (mm
 1) 74.19 4.68 49.88 3.52
d
TPF (mm
 1) 3.8 0.8 -4.7 1.2
d
Ct.Th. (mm) 187.7 1.7 227.8 5.7
d
Histomorphometry of cancellous bone
f
OS/BS 3.8 0.8 9.1 2.5
c
Ob.S/BS 3.6 0.8 8.7 2.3
c
MS/BS 15.6 1.8 29.2 4.5
e
BFR 35 66 4  10
e
Oc.S/BS 1.2 0.2 1.9 0.2
ES/BS 4.7 0.6 4.7 0.7
ap<.0001,
bp<.01,
cp¼.06,
dp<.001,
ep<.05 vs. WT.
fAbbreviations are defined in ‘‘Materials and Methods.’’
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surface (MS/BS) in Gpr30 KO mice (15.6% versus 29.2%, p¼.02;
Table 1 and Fig. 5) and BFR (35 versus 64mm
3/mm
2/yr, p¼.04).
There was a strong trend toward increased osteoid (OS/BS) and
osteoblastic (Ob.S/BS) surfaces in Gpr30 KO mice (p¼.06 versus
WT mice; Table 1). There was no significant change in osteoclast
(Oc.S/BS) or eroded (ES/BS) surfaces (Table 1).
Gpr30 inactivation has stage-specific effects on in vitro
osteoblast differentiation
To assess the effect of Gpr30 inactivation on cell autonomous
osteoprogenitor differentiation, bone marrow–derived cells
were cultured in vitro under osteogenic differentiation condi-
tions. In the early culture period (day 7), there was a pronounced
decrease in alkaline phosphatase positivity, consistent with a
decrease in osteoblast precursor number or proliferation (Fig. 6A,
B). On the other hand, late-stage cultures, usually 15 to 20 days,
showed an increased number of mineralized nodules in the
Gpr30 KO cultures (Fig. 6C, D).
Discussion
GPR30 expression has been shown in human
(26,27) and mouse
bone (Ford and Oz, unpublished results), although its function in
bone is only beginning to be explored. Gene deletion of the
receptor provided a model to determine its role in male skeletal
homeostasis. This report demonstrates for the first time in male
micethatinactivationofGPR30signaling causesabnormalities in
body size, bone mass, and bone microarchitecture. Gpr30 KO
BMD was increased on DXA scans, and mCT evaluation of the
distal femur revealed an increase in cortical thickness and in
trabecular bone thickness, volume, and connectivity. This in-
creased bone mass was associated with increased mineralized
surface by quantitative dynamic histomorphometry. In vivo BrdU
labeling revealed increased proliferative activity in the femoral
growth plate of 4-month-old Gpr30 null mice, suggesting that
the receptor is important to cessation of growth plate prolife-
rative activity.
Previous Gpr30 transgenic and KO mouse models have been
constructed to study the in vivo function of this protein.
(29–32)
Wang and colleagues created a Gpr30 KO by insertional muta-
genesis using homologous recombination to insert a Neo
cassette into exon 3.
(29) These investigators focused on thymic
biology to show that GPR30 contributes to estrogen-induced
thymicatrophyandthymocyte apoptosisbutnotdevelopmental
blockade of thymocytes, which seems to be mediated by ERa.
Subsequent studies on these mice by Haas and colleagues
showed that Gpr30 deletion results in loss of the normal
abrogation of vasoconstrictor-induced changes in vascular tone
and increased visceral fat.
(38) Isnee and colleagues reported on
Gpr30-lacZ mice in which homologous recombination was used
to replace exon 3 of the Gpr30 locus by the lacZ reporter
cassette.
(30) In support of a role for GPR30 function in endothelial
cells, the authors found lacZ expression in vascular beds of small
arteries in multiple organs, including the heart, reproductive
tract, and breast. They also found decreased levels of CD4
þ and
CD8
þ T cells in the blood, which is consistent with increased the
T-cell apoptosis reported by Wang and colleagues. In contrast to
the mice generated by Wang and colleagues, the authors did not
observeincreasedvisceralfat.Ottoandcolleagueshavereported
Gpr30KO micegenerated usingCre-loxtechnology.
(31) Thestudy
placed emphasis on the reproductive tract, for which the authors
Fig. 4. Gpr30 KO mice have increased trabecular bone volume and
connectivity in the distal femur. (A) Coronal section of WT and Gpr30
KO femurs showing an increase in trabecular bone and cortical thickness.
Images not to scale. (B) Representative 3D rendering of the distal femoral
trabecular network of WT mice. (C) Representative 3D rendering of the
distal femoral trabecular network of Gpr30 KO mice.
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with phenotypes observed in other models of GPR30 deficiency.
Studying the effects of estradiol therapy on the uterus and
mammary gland, they observed no difference in the response of
10-week-old castrated WT and Gpr30 KO mice. The lack of an
observed effect could reflect no role for GPR30 in the responses
studied, that the dosing regimen did not reflect normal
physiologic fluctuation in serum E levels in animals, or that
the function of traditional ERs is dominant at the concentrations
used. Martensson and colleagues also reported a Gpr30 KO
mouse created by using Cre-lox technology to delete exon 3.
(32)
These investigations placed emphasis on metabolic and
cardiovascular phenotypes. Abnormalities in glucose tolerance,
blood pressure, and estradiol-stimulated insulin release were
observed in female but not male knockouts. All combined, it is
clear that previous studies using genetically altered Gpr30 mice
have emphasized immunologic, cardiovascular, metabolic, and
reproductive phenotypes.
Before now, skeletal studies have been published for only one
of the mouse models. Martensson and colleagues showed that
genetic inactivation of GPR30 caused decreased crown-rump
and femur lengths in 3-month-old female Gpr30 KO mice but
reported that there was no effect on the skeleton of male
mice.
(32) Subsequently, using the same mice Windahl and
colleagues showed that, as in WT mice, ovariectomy-induced
corticalandtrabecularbonelosscouldbepreventedinestrogen-
treated female Gpr30 KO mice, suggesting that GPR30 is not
necessary for the prevention of bone loss after castration;
Fig. 5. GPR30 deficiency results in increased mineralized surface in tibial cancellous bone. (A) Representative microphotograph of tetracycline-labeled
cancellous bone in WT mice. Both single- and double-labeled surfaces are present. (B) Representative microphotograph of tetracycline-labeled cancellous
bone in Gpr30 KO mice. There is a greater extent of labeled surface compared with WT mice. Magnification bar¼100mm.
Fig. 6. Gpr30 KO osteoprogenitors show decreased colony number in early osteoblast differentiation but increased mineralized nodules in late-stage
differentiation. In vitro osteoclastogenesis is unaffected by GPR30 deficiency. (A) Representative image of CFU-F colony staining for alkaline phosphatase
from WT and Gpr30 KO cultures. (B) Quantization of macroscopic CFU-F alkaline phosphatase
þ colonies. (C) Representative image of mineralized nodules
(CFU-Ob) stained with alizarin red (S) from WT and Gpr30 KO cultures. LPF¼ low-power field. (D) Quantization of macroscopic mineralized nodules
produced in CFU-Ob cultures. (E). Representative images of osteoclast formation induced by sRANKL and M-CSF stimulation of WT and Gpr30KO bone
marrowcells. (F) Quantizationofosteoclastformation.
 p<.05versusWT.The imagesarerepresentative results fromanexperimentrepeatedthreetimes.
304 Journal of Bone and Mineral Research FORD ET AL.however, unlike in WT mice, E treatment did not reduce growth
plate height in the Gpr30 KO mice.
(33) Studies of male mice were
not reported. These results indicate that estradiol action through
GPR30 is compartment-dependent and required for normal
estrogenic response in the growth plate of female mice. The
sexually dimorphic impact of GPR30 deficiency is reminiscent of
other models of deficient estrogen action.
(9,11) As in our studies
reportedhere,serumIGF-1levelswerenotalteredintheirmodel.
On the other hand, the lack of an observed male skeletal
phenotype in their model of GPR30 deficiency contrasts with our
observations of increased bone mass, body and femur length,
and growth plate activity. The different results obtained with
the models may be related to factors such as age, genetic
background, diet (e.g., phytoestrogen content), or technology
used to create the mice. In the mice studied by Martensson and
colleagues and Windahl and colleagues, the mutation is carried
on a mostly B6 background, whereas our mice were of a hybrid
129/B6 background. It is possible that genetic loci outside the
Gpr30 locus modify the phenotypes in a strain-dependent
fashion. Another possibility relates to the impact that mutations
of the Gpr30 locus may have on an overlapping locus, C7orf50
(GeneID 84310, Entrez Gene database). This open reading frame
is transcribed in the opposite direction and codes for a
hypothetical 194-amino-acid protein of unknown function. In
both models, intronic sequence is altered, whether by deletion
(Martensson model) or by insertional disruption (our model).
Such alterations in introns may affect expression of proteins.
(39)
One might speculate that C7orf50 expression is differently
affected in the two models and that it has some role, direct or
indirect, in bone homeostasis. Even if the two Gpr30 KO mouse
models differ with respect to impact on C7orf50, the sexually
dimorphic effect of the knockout in the Martensson model still
remains unexplained. Concern also has been raised about the
presence of the Neo cassette in our model.
(30) While we cannot
rule out the theoretical possibility of nontarget effects of the Neo
cassette, the fact that others have observed similar effects on
earlyosteoblast proliferationandsuppression ofchondrogenesis
(proliferation was not specifically measured) using completely
different systems gives us confidence in the fidelity of our
results.
(28,40) We should point out it also has been reported that
the Cre-lox approach used by the other authors may result in
unrecognized chromosomal rearrangements.
(41) Whatever is the
explanation for the phenotypic differences between the two
models, it is clear from results of both groups that GPR30 is a
critical receptor in regulation of the growth plate.
It is now widely accepted that estrogens regulate longitudinal
bone growth. In human males, it is believed the pubertal growth
spurt is initiated by estrogens.
(42) On the other hand, the lack of
growth plate fusion in aromatase deficient (ArKO) and ERa KO
patients established that estrogen action through ERa causes
termination of long bone growth through growth plate fusion.
Unlike in humans, growth plate fusion does not occur in mice,
but growth plate closure, characterized by a marked decrease in
proliferative activity, does. Despite this species difference, the
fundamentals of chondrocyte proliferation should be consistent
across species. The increased BrdU labeling observed in the
GPR30-deficient growth plate showed a clear increase in
proliferationofchondrocytesandisconsistentwiththeobserved
increased long bone growth phenotype in Gpr30 KO mice. It
establishes arole for GPR30 inchondrocytes, in whichit serves as
a ‘‘brake’’ to slow chondrocyte proliferation. Furthermore, in
male rodent knockouts of estrogen action, only the Gpr30 KO
recapitulatesthepersistentgrowthplateactivitythatleadstothe
continued linear growth observed in humans.
(43) With this
observation, it is reasonable to infer that, at least in male mice,
GPR30 action functions to limit longitudinal skeletal growth.
Whether it plays the same role in humans awaits case reports of
patients with GPR30 deficiency; however, it is noteworthy that
GPR30 expression in the human has been shown to change with
age during puberty, and it is postulated to regulate longitudinal
bone growth.
(26) Conceivably, at low doses, when E is postulated
to stimulate long bone growth,
(42) the conventional ERs are
dominant. On the other hand, at higher doses of E, the action of
GPR30 may come into play,
(44) thereby limiting or terminating
long bone growth.
In contrast to our results, previous studies on Ar KO
(9,10) or ERa
KO
(45) male mice have shown decreased femoral length or no
change in the complete ERa KO mice.
(11) This is opposite of the
finding in most Ar KO patients and in the one reported ERa KO
patient. The molecular basis for this species difference is unclear;
however, Ar KO and ERa KO mice have high testosterone levels,
which are known to have antiproliferative effects on chondro-
cyte proliferation.
(46) Gpr30 KO mice do not have elevated
testosterone as a confounding factor.
(32) Therefore, the model
will be a valuable resource in unraveling estrogen’s action on the
growth plate.
To begin to unravel the cellular mechanisms that account for
the high BMD phenotype, we undertook differentiation studies
of bone marrow cells cultured under osteogenic and osteoclas-
togenic conditions. Despite previous studies reporting GPR30
expression in osteoclasts, we did not observe any changes in
osteoclastic surface, eroded surface, or in vitro differentiation
from precursors cells. Therefore, its function remains to be
determined in osteoclasts. On the other hand, our in vitro results
demonstrated a bifunctional role for GPR30 during osteoblast
differentiation. Early-stage osteoblastic in vitro differentiation
cultures showed a decrease in alkaline phosphatase
þ colony
number, consistent with decreased proliferation. The results are
consistent with a previous report on mouse osteoblast pro-
genitors that showed Gpr30 is a Runx2-responsive gene and acts
in a promitogenic fashion through a Cdk pathway.
(28) Taken
together, these observations are consistent with a model in
which GPR30 signaling stimulates proliferation of immature
osteoblasts. Moreover, considering our results showing increas-
ed proliferation in the GPR30-deficient growth plate, it seems
that GPR30 functions in bone as a pro- or antiproliferative factor
in a cell-specific fashion. This aspect of GPR30 activity has been
discussed recently in cancer cell lines.
(47) In contrast to results
from these cell autonomous assays, in vivo we not observe a
change in osteoblast surface/number. It should be noted that we
did not directly measure osteoblast proliferation or apoptosis in
vivo and that within the complex bone microenvironment, other
factors may compensate for the decreased proliferation in
cultured GPR30-deficient osteoblasts. Late-stage cultures, under
osteogenic conditions, showed increased mineralized nodule
formation by cells deficient in GPR30. This suggests that GPR30
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aspect of GPR30 function may be a mechanism through which
the in vivo increased BMD phenotype was achieved. Indeed,
dynamic histomorphometry studies showed higher indices of
mineralization (MS/BS) and osteoid formation (OS/BS) in Gpr30
KO mice. Increased skeletal loading from the greater body
weight conceivably could contribute to high bone mass in Gpr30
KO mice. While the relationship between body mass and bone
mass is complex,
(48) we would expect that increased mechanical
loading of the tibias from greater weight to affect osteoclasts,
leadingto,ifanything,decreasedresorptionrelativetoformation
in a load-bearing limb.
(49) On histologic evaluation (Table 1), we
did not observe a decrease in osteoclast or eroded surface.
Therefore, we do not think that body mass is the driver of the
bone phenotype. While the underlying molecular mechanisms
remain to be defined, the increased bone mass points to a
potential therapeutic opportunity, inhibition of GPR30 to
increase BMD.
A number of the signaling pathways downstream of Gpr30
have been defined mainly in cells other than bone, particularly
breast cancer cells. This has been the subject of excellent recent
reviews, but suffice it to say that these include rapid activa-
tion of MAP kinase, SRC-like tyrosine kinase, and adenylate
cyclase.
(44,50,51) The latter is of particular interest in bone biology
because cAMP is the second messenger used by the most
well-known GPCRs in bone, namely, the parathyroid hormone/
parathyroid hormone–related protein (PTH/PTHrP) receptor and
the prostaglandin receptors EP1 to EP4. The PTH receptor acts in
part by stimulating cAMP production, and receptors EP2 and EP4
act by stimulating cAMP production. Furthermore, like GPR30, all
are expressed in osteoblasts, and chondrocytes. Therefore, one
mightpostulatetheexistenceoffunctionalredundancybetween
GPR30 and these other GPCRs in bone. Thus it might be
surprising that Gpr30 KO mice have a bone phenotype. Several
considerations are important here. First, the duration and
intensity of the signal generated by the receptors may differ.
Even the effect of PTH itself on bone differs according to dosing
regimen. PTH, when given in a pulsatile fashion, is anabolic to
bone. On the other hand, continuous high levels of PTH, as in
hyperparathyroidism, cause bone loss. Second, the outputs and
targets/consequences of the signaling pathways may differ. For
instance, PTH has been shown to inhibit osteoblast proliferation,
whereas estrogen stimulates it. Of note and consistent with our
currentresultsarerecentinvitrostudiesreportedbyTeplyukand
colleagues that showed that GPR30’s action in early osteoblas-
togenesis is proproliferative,
(28) suggesting that the proliferative
effects of estrogen may be mediated in part by GPR30. Finally,
since it is known that there are different cyclases, even if GPR30
shares second messengers with other GPCRs in bone, the
receptors’ signaling pathways may involve different cyclases.
In summary, this study demonstrates that GPR30 is important
to regulation of proliferation within the male mouse growth
plate and to bone volume within cancellous bone. The
underlying mechanisms apparently do not require changes in
circulating IGF-1. This is the first male mouse model with
deficient estrogen action that reproduces the long bone growth
abnormality seen in human Ar KO or ERa KO patients.
Understanding the molecular mechanisms by which GPR30
regulates osteoblast function and proliferative activity within the
growth plate not only will increase our understanding of basic
bone biology but also may lead to novel therapies for short
stature and low bone mass.
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